George Solomon
Critical Care Medicine · Birmingham, ALNPI 1316140403
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Insmed, Inc. accounts for 63.7% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $40,910 and has fallen 89.9% since, to $4,129 in 2025. Among critical care medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $678.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$72K
- Vertex$17K
- GSK$11K
- Electromed, Inc.$5K
- AstraZeneca$3K
- Genentech, Inc.$2K
- plus $2K from 12 others
Across 541 payments — averaging $2341.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$737K
- Vertex$422K
- AstraZeneca$63K
- Sanofi US Services Inc.$41K
- Boehringer Ingelheim International GmbH$3K
What the payments were for
- Consulting fees$59,91753%
- Speaking & faculty fees$27,22524%
- Travel & lodging$18,89917%
- Food & beverage$6,6246%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 84 | $71,742 |
| Vertex | 12 | $17,219 |
| GSK | 1 | $11,368 |
| Electromed, Inc. | 43 | $5,500 |
| AstraZeneca | 1 | $3,222 |
| Genentech, Inc. | 1 | $1,980 |
| Astrazeneca UK Limited | 1 | $537 |
| Philips North America LLC | 8 | $485 |
| Boehringer Ingelheim | 2 | $189 |
| Alcresta Therapeutics, Inc. | 2 | $131 |
| AbbVie | 1 | $101 |
| Genentech USA, Inc. | 2 | $55 |
| Baxter Healthcare | 2 | $47 |
| Chiesi USA, Inc. | 1 | $33 |
| Abbott | 2 | $32 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$112,677 in reported general payments places this provider in the 95th percentile of 73 critical care medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 81 | $2,046,113 |
| ZenpepLipase/Protease/Amylase | 15 | $121,495 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $112,851 |
| Dupixent PenDupilumab | 12 | $40,960 |
| EliquisApixaban | 17 | $9,546 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $9,419 |
| MultaqDronedarone Hcl | 12 | $9,088 |
| Azithromycin | 144 | $5,161 |
| Meropenem | 19 | $4,678 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $2,797 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 90 | $2,672 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $2,511 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,958 |
| Fluticasone Propionate | 25 | $534 |
| Diphenhydramine Hcl | 18 | $489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $17,219 | $2,046,11381 claims |
| GSKBreo Ellipta | $11,368 | $9,41919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 critical care medicine providers in Alabama.
Other critical care medicine in Birmingham
- James WellsBirmingham$223K
- Mark DransfieldBirmingham$160K
- Tracy LuckhardtBirmingham$28K
- Keith WilleBirmingham$9K
- Victor ThannickalBirmingham$8K
- Vipul ShahBirmingham$6K
- Samuel McElweeBirmingham$5K
- Nicole SchreinerBirmingham$4K
- David LafonBirmingham$4K
- Dhaval RavalBirmingham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.